Ibrutinib, a first‐generation Bruton's tyrosine kinase (BTK) inhibitor, is now considered a standard treatment for patients diagnosed with Waldenström macroglobulinemia (WM). This evidence concerns the gene BTK and Waldenstrom macroglobulinemia.